KPIs & Operating Metrics(New)
Growth Metrics

Chemed (CHE) EBITDA Margin (2016 - 2026)

Chemed filings provide 18 years of EBITDA Margin readings, the most recent being 15.04% for Q1 2026.

  • For the quarter ending Q1 2026, EBITDA Margin fell 169.0% year-over-year to 15.04%, compared with a TTM value of 15.09% through Mar 2026, down 266.0%, and an annual FY2025 reading of 15.53%, down 172.0% over the prior year.
  • EBITDA Margin hit 15.04% in Q1 2026 for Chemed, down from 17.9% in the prior quarter.
  • The five-year high for EBITDA Margin was 21.23% in Q4 2023, with the low at 33.08% in Q4 2022.
  • Median EBITDA Margin over the past 5 years was 17.0% (2024), compared with a mean of 14.01%.
  • The largest YoY upside for EBITDA Margin was 5432bps in 2023 against a maximum downside of -487bps in 2023.
  • Year by year, EBITDA Margin stood at 33.08% in 2022, then soared by 164bps to 21.23% in 2023, then fell by -6bps to 19.87% in 2024, then dropped by -10bps to 17.9% in 2025, then dropped by -16bps to 15.04% in 2026.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 15.04%, 17.9%, and 14.15% for Q1 2026, Q4 2025, and Q3 2025 respectively.